AbbVie is acquiring Landos Biopharma, whose lead drug is a small molecule that takes a novel approach to treating ulcerative colitis. Preliminary proof-of-concept data from a Phase 2 study are expected later this year.
AbbVie Gets Another Ulcerative Colitis Contender via $137M Landos Acquisition
